Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 3, 2014, Pages 409-424

  Dézsi, Livia ^a   Vécsei, László ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Continuous dopaminergic stimulation; Dopamine agonists; Kynurenines; Levodopa; Levodopa pharmacokinetics; Levodopa carbidopa intraintestinal gel therapy; Monoamine oxidase B inhibitors; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE; LEVODOPA;

ANIMAL; BLOOD; DISEASE MODEL; HUMAN; PARKINSON DISEASE;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 84894195926     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.878702     Document Type: Review

References (118)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009;373:2055-66
2. Stocchi F. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. Parkinsonism Relat D 2009;15:S9-S15 . This paper and paper [60] give a good insight into the continuous dopaminergic stimulation hypothesis and therapeutic approaches respectively.
3. Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies. Neurology 1989;39(Suppl 2):25-38
4. Leon AS, Speigel H. The effect of antacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol 1972;12:263-7
5. Edwards LL, Quingley EMM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: Frequency and pathophysiology. Neurology 1992;42:726-32
6. Djaldetti R, Baron J, Ziv I, et al. Gastric emptying in Parkinson's disease: Patients with and without response fluctuations. Neurology 1996;46:1051-4
7. Müller T, Erdmann C, Bremen D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 2006;29:61-7
8. Gabrielli M, Bonazzi P, Scarpellini E, et al. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2011;26:889-92
9. Stocchi F, Ruggieri S, Monge A, et al. Clinical efficacy of single morning doses of different levodopa formulations. Clin Neuropharmacol 1994;17(Suppl 3):S16-20
10. Stocchi F, Barbato L, Bramante L, et al. Fluctuating parkinsonism: A pilot study of single afternoon dose of levodopa methyl ester. J Neurol 1996;243:377-80
11. Stocchi F, Fabbri L, Vecsei L, et al. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol 2007;30:18-24
12. Pierantozzi M, Pietroiusti A, Brusa L, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 2006;66:1824-9
13. Lee WY, Yoon WT, Shin HY, et al. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord 2008;23:1696-700
14. Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013; published online 9 April 2013, doi: 10.1002/mds.25522 . This paper is of interest for the role of SIBO in PD.
15. Rahne KE, Tagesson C, Nyholm D. Motor fluctuations and Helicobacter pylori in Parkinson's disease. J Neurol 2013;260(12):2974-80
16. Gasbarrini A, Lauritano EC, Gabrielli M, et al. Small intestinal bacterial overgrowth: Diagnosis and treatment. Dig Dis 2007;25:237-40
17. PoeweW Antonini A, Zijlmans JCM, et al. Levodopa in the treatment of Parkinson's disease: An old drug still going strong. Clin Interv Aging 2010;5:229-38 . This paper summarizes the evidences regarding the use of LD for PD treatment.
18. Stocchi F. Optimising levodopa therapy for the management of Parkinson's disease. J Neurol 2005;252(Suppl 4):43-8
19. Mitsuoka T, Kaseda Y, Yamashita H, et al. Effects of nicotine chewing gum on UPDRS score and P300 in early-onset parkinsonism. Hiroshima J Med Sci 2002;51:33-9
20. Huang LZ, Grady SR, Quik M. Nicotine reduces L-DOPA-induced dyskinesias by acting at beta 2 nicotinic receptors. J Pharmacol Exp Ther 2011;338:932-41
21. Zhang D, Mallela A, Sohn D, et al. Nicotinic receptor agonists reduce L-dopa-induced dyskinesias in a monkey model of Parkinson's disease. J Pharmacol Exp Ther 2013;347(1):225-34
22. Ling H, Petrovic I, Day BL, et al. Smoking-induced transient motor deterioration in a levodopa-treated patient with Parkinson's disease. J Neurol 2012;259:2419-23
23. Villafane G, Cesaro P, Rialland A, et al. Chronic high dose transdermal nicotine in Parkinson's disease: An open trial. Eur J Neurol 2007;14:1313-16
24. Kelton MC, Kahn HJ, Conrath CL, et al. The effects of nicotine on Parkinson's disease. Brain Cogn 2000;43:274-82
25. Vieregge A, Sieberer M, Jacobs H, et al. Transdermal nicotine in PD: A randomized, double-blind, placebocontrolled study. Neurology 2001;57:1032-5
26. Kyaw WT, Nagai M, Kaneta M, et al. Effect of nicotine on the pharmacokinetics of levodopa. Clin Neuropharm 2013;36:46-51
27. Murata M, Mizusawa H, Yamanouchi H, et al. Chronic levodopa therapy enhances dopa absorption: Contribution to wearing-off. J Neural Transm 1996;103:1177-85
28. Murata M. Levodopa in the early treatment of Parkinson's disease. Parkinsonism Rel Dis 2009;15(Suppl):S17-20
29. Available from: Http://www.medmerits. com/index.php/article/levodopa/P1
30. Nutt JG, Woodward WR, Anderson JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism. Ann Neurol 1985;18:537-43
31. Available from: Http://www.inchem.org/documents/pims/pharm/levedopa. htm#SubSectionTitle:3.4.4% 20Bioavailability
32. Rezak M. Current pharmacotherapeutic options in Parkinson's disease. Dis Mon 2007;53:214-22
33. Kuoppamäki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 2009;65:443-55
34. Hauser RA, Lyons KE, McClain T. Parkinson disease. Available from: Http://emedicine.medscape.com/article/1831191-overview . This is a thorough review on PD.
35. Hauser RA, Panisset M, Abbruzzese G, et al. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2009;24:541-50
36. Available from: Www.pdtrials.org/en/clinical-research-news/release/pr- 1236180097
37. Haasio K. Toxicology and safety of COMT inhibitors. Int Rev Neurobiol 2010;95:163-89
38. Available from: Http://www.mayoclinic. com/health/drug-information/ DR600837/DSECTION=side-effects . This reference and reference [39] include description and side effects of levodopa.
39. Available from: Http://www.drugs.com/monograph/levodopa-carbidopa. html#r104 . This reference and reference [38] include description and side effects of levodopa.
40. Available from: Http://www. reverseparkinsons.net/blog/side-effects- ofmedication/medication-is-there-aconnection- between-melanoma-levodopaand- pd.html
41. Antonini A, Abbruzzese G, Barone P, et al. COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): Relevance for motor and non-motor features. Neuropsychiatr Dis Treat 2008;4:1-9
42. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson's disease. Arch Neurol 2006;63:1756-60
43. Lokk J. Treatment with levodopa can affect latent vitamin B 12 and folic acid deficiency. Patients with Parkinson disease runt the risk of elevated homocysteine levels. Lakartidningen 2003;100:2674-7
44. Smith Y, Wichmann T, Factor SA, et al. Parkinson's disease therapeutics: New developments and challenges since the introduction of levodopa. Neuropsychopharmacol Rev 2012;37:213-46. This paper is a thorough review of the therapies in use for Parkinson's disease and the future targets.
45. Agid Y. Levodopa: Is toxicity a myth? Neurology 1998;50:858-63
46. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: Current controversies. Mov Disord 2004;19:997-1005
47. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508
48. Schapira AH. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 2009;72:S44-50
49. Schapira AH, Agid Y, Barone P, et al. Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Eur J Neurol 2009;16:1090-9
50. Sethi KD. The impact of levodopa on quality of life in patients with Parkinson disease. Neurologist 2010;16:76-83
51. Jenner P, McCreary AC, Scheller DK. Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression. J Neural Transm 2011;118:1691-702
52. Piedad JCP, Cavanna AE. Dyskinesias and treatment with pramipexole in patients with Parkinsons disease. Parkinsons Dis 2012, doi:10.1155/2012/473769 . This paper is of interest for effects of pramipexole on dyskinesias.
53. Widnell K. Pathophysiology of motor fluctuations in Parkinson's disease. Mov Disord 2005;20(Suppl 11):S17-22
54. Ngwuluka N, Pillay V, Du Toit LC, et al. Levodopa delivery systems: Advancements in delivery of the gold standard. Expert Opin Drug Deliv 2010;7:203-24
55. Calandrella D, Antonini A. Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. Parkinsonism Relat Disord 2012;18(Suppl 1):S120-2
56. Damier P, Tremblay L, Feger J, et al. Development of dyskinesias induced by treatment for Parkinson's disease: Potential role of first exposure to L-DOPA (priming). Rev Neurol 2000;156:224-35
57. Jenner P. Avoidance of dyskinesia: Preclinical evidence for continuous dopaminergic stimulation. Neurology 2004;62:S47-55
58. Pahwa R, Factor SA, Lyons KE, et al.; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66(7):983-95
59. Bibbiani F, Costantini LC, Patel R, et al. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 2005;192:73-8
60. Wright BA, Waters CH. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease. Expert Rev Neurother 2013;13:719-29 . This paper and paper [2] give a good insight into the continuous dopaminergic stimulation hypothesis and therapeutic approaches respectively.
61. Nyholm D, Odin P, Johansson A, et al. Pharmacokinetics of levodopa, carbidopa and 3-O-methyldopa following 16-h jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. AAPS 2012;15:316-23
62. Westin J, Nyholm D, Palhagen S, et al. A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. Clin Neuropharmacol 2011;34:61-5
63. Müller T. Drug therapy in patients with Parkinson's disease. Translational Neurodeg 2012;1:10
64. Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: Selection criteria and patient management. Expert Rev Neurother 2009;9:859-67
65. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: Scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87
66. Klostermann F, Jugel C, Müller T, et al. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 2012;119:369-72
67. Müller T, van Laar T, Cornblath DR, et al. Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 2013;19:501-7
68. Fernandez HH, Vanagunas A, Odin P, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism Relat Disord 2013;19:339-45
69. Brooks DJ. Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: Implications from a clinical and patient perspective. Neuropsychiatr Dis Treat 2008;4:39-47
70. Hauser RA. IPX066: A novel carbidopa-levodopa extended-release formulation. Expert Rev Neurother 2012;12:133-40
71. Hauser RA, Ellenbogen AL, Metman LV, et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov Disord 2011;26:2246-52
72. Hauser RA, Hsu A, Kell S, et al. IPX066 ADVANCE-PD investigators. Extended release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: A Phase 3 randomised, double-blind trial. Lancet Neurol 2013;12:346-56
73. Obeso JA, Olanow W. Continuing efforts to obtain continuous delivery of levodopa. Mov Disord 2011;26:2149-50
74. Abbruzzese G, Barone P, Bonucelli U, et al. Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: Efficacy, safety and patient selection. Functional Neurol 2012;27:147-54
75. Nutt GJ. Continuous dopaminergic stimulation: Is it the answer to the motor complications of levodopa? Mov Disord 2007;22:1-9
76. Knoll J, Ecsery Z, Magyar K, et al. Novel (-)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action. Biochem Pharmacol 1978;27:1739-47
77. Kincses ZT, Vecsei L. Pharmacological therapy in Parkinson's disease: Focus on neuroprotection. CNS Neurosci Ther 2011;17:345-67
78. Magyar K, Palfi M, Tabi T, et al. Pharmacological aspects of deprenyl. Curr Med Chem 2004;11:2017-31
79. Mahmood I. Clinical Pharmacokinetics and pharmacodynamics of seleginline. An update. Clin Pharmacokinet 1997;33:91-102
80. Tabi T, Szöko E, Vecsei L, et al. The pharmacokinetic evaluation of selegiline (ODT) for the treatment of Parkinson's disease. Expert Opin Drug Metab Toxicol 2013;9:699-712
81. Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor for the treatment of Parkinson's disease. Clin Ther 2007;29:1825-49
82. Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after l-deprenyl (selegiline) withdrawal. Synapse 1994;18:86-93
83. de Marcaida JA, Schwid SR, White WB, et al.; For Parkinson Study Group TEMPO and the PRESTO tyramine substudy investigators and coordinators. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 2006;21:1716-21
84. Panisset M, Schwid SR, Ondo W, et al. Safety of concomitant therapy with rasagiline and antidepressants in Parkinson's disease. Mov Disord 2007;223(Suppl 16):S104-5
85. Minguez-Minguez S, Solis-Garcia del Pozo J, Jordan J. Rasagiline in Parkinson's disease: A review based on meta-analysis of clinical data. Pharmacol Res 2013;74:78-86
86. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287(13):1653
87. Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease. Drugs Aging 2010;27:295-310
88. Parkinson Study Group. Pramipexole vs levodopa as initial treatment of Parkinson's disease: A randomized controlled trial. JAMA 2000;284:1931-8
89. Brodsky MA, Park BS, Nutt JG. Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson's disease. Arch Neurol 2010;67:27-32
90. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: A double-blind, double-dummy, randomized controlled trial. Lancet Neurol 2007;6:513-20
91. Eisenreich W, Sommer B, Hartter S, et al. Pramipexole extended release: A novel treatment option in Parkinson's disease. Parkinsons Dis 2010;2010:612619
92. Antonini A, Calandrella D. Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: Implications for patients. Neuropsych Dis Treat 2011;7:297-302
93. Poewe W, Rascol O, Barone P, et al. Extended-release pramipexole in early Parkinson disease: A 33-week randomized controlled trial. Neurology 2011;77:759-66
94. Stacy M, Silver D. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. Parkinsonism Relat Dis 2007;14:85-92
95. Jankovic J, Aguilar G. Current approaches to treatment of Parkinson's disease. Neuropsychiatr Dis Treat 2008;4:743-57
96. Braun M, Cawello W, Poole K, et al. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease. Eur J Neurol 2005;12(Suppl 2):96
97. Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-6
98. Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: A randomised, double-blind, placebocontrolled trial. Lancet Neurol 2008;7:595-604
99. Kim HJ, Jeon BS, Lee WY, et al. Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease. BMC Neurol 2011; published online 10 August 2011, doi:10.1186/1471-2377-11-100. Available from: Http://www. biomedcentral.com/1471-2377/11/100
100. Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: Administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 2009;37:2055-60
101. Swart PJ, Oelen WE, Bruins AP, et al. Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UVatmospheric pressure ionization mass spectrometry. J Anal Toxicol 1994;18:71-7
102. Cawello W, Wolff HM, Meuling WJ, et al. Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: A mass balance trial. Clin Pharmacokinet 2007;46:851-7
103. Available from: Www.clinicaltrials.gov
104. Poewe W, Mahlknecht P, Jankovic J. Emerging therapies for Parkinson's disease. Curr Opin Neurol 2012;25:448-59 . This review covers the therapies in use for Parkinson's disease.
105. Schapira AH, Stocchi F, Borgohain R, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Eur J Neurol 2013;20:271-80
106. Szabo N, Kincses ZT. Vecsei L. novel therapy in Parkinson's disease: Adenosine A(2A) receptor antagonists. Expert Opin Drug Metab Toxicol 2011;7:441-55
107. Zadori D, Szalardy L, Toldi J, et al. Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease. J Neural Transm 2013;120:673-81
108. Chase TN, Oh JD. Striatal dopamineand glutamate-mediated dysregulation in experimental parkinsonism. TINS 2000;23:86-91
109. Elahi B, Sun X, Chen R. Effects of NMDA receptor antagonists on levodopa induced dyskinesia. Meta analysis of controlled clinical trials. Mov Disord 2009;24(Suppl 1):S263
110. Vamos E, Pardutz A, Klivenyi P, et al. The role of kynurenines in disorders of the central nervous system: Possibilities for neuroprotection. J Neurol Sci 2009;283:21-7
111. Zadori D, Klivenyi P, Vamos E, et al. Kynurenines in chronic neurodegenerative disorders: Future therapeutic strategies. J Neural Transm 2009;116:1403-9
112. Nemeth H, Toldi J, Vecsei L. Kynurenines, Parkinson's disease and other neurodegenerative disorders: Preclinical and clinical studies. J Neurol Transm 2006;70:285-304
113. Vecsei L, Szalardy L, Fülöp F, et al. Kynurenines in the CNS: Recent advances and new questions. Nat Rev Drug Discov 2013;12:64-82. This publication and paper [114] are of particular interest for the mechanism of action of kynurenines and their properties.
114. Zadori D, Klivenyi P, Toldi J. Kynurenines in Parkinson's disease: Therapeutic perspectives. J Neural Transm 2012;119:275-83. This publication and paper [113] are of particular interest for the mechanism of action of kynurenines and their properties.
115. Hartai Z, Klivenyi P, Janaky T, et al. Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. J Neurol Sci 2005;239:31-5
116. Szabo N, Kincses ZT, Toldi J, et al. Altered tryptophan metabolism in Parkinson's disease: A possible novel therapeutic approach. J Neurol Sci 2011;310:256-60
117. Gregoire L, Rassoulpour A, Guidetti P, et al. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav Brain Res 2008;186:161-7
118. Knyihar-Csillik E, Csillik B, Pakaski M, et al. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. Neuroscience 2004;126:899-914